A detailed history of State Street Corp transactions in Dia Medica Therapeutics Inc. stock. As of the latest transaction made, State Street Corp holds 68,729 shares of DMAC stock, worth $275,603. This represents 0.0% of its overall portfolio holdings.

Number of Shares
68,729
Previous 68,729 -0.0%
Holding current value
$275,603
Previous $202,000 42.08%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$2.16 - $3.66 $4,536 - $7,686
2,100 Added 3.15%
68,729 $202,000
Q1 2022

May 16, 2022

BUY
$2.29 - $3.88 $15,828 - $26,818
6,912 Added 11.57%
66,629 $167,000
Q4 2021

Feb 14, 2022

BUY
$3.43 - $4.65 $68,600 - $93,000
20,000 Added 50.36%
59,717 $223,000
Q3 2021

Nov 15, 2021

BUY
$3.1 - $4.32 $29,450 - $41,040
9,500 Added 31.44%
39,717 $159,000
Q2 2021

Aug 16, 2021

BUY
$4.45 - $9.91 $134,465 - $299,450
30,217 New
30,217 $134,000

Others Institutions Holding DMAC

About DiaMedica Therapeutics Inc.


  • Ticker DMAC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 26,443,100
  • Market Cap $106M
  • Description
  • DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...
More about DMAC
Track This Portfolio

Track State Street Corp Portfolio

Follow State Street Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of State Street Corp, based on Form 13F filings with the SEC.

News

Stay updated on State Street Corp with notifications on news.